

FOI 3388

6th November 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

A. How many patients have been treated with the following drugs in the past 4 months:

Atogepant (Aquipta) – any disease

Response:

Information not held

Erenumab (Aimovig) - any disease

Response:

Information not held

Eptinezumab (Vyepti) – any disease

Response:

6 patients

Fremanezumab (Ajovy) - any disease

Response:

<5

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they

would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Galcanezumab (Emgality) - any disease

Response:

<5

The Trust has a legal duty to protect patient confidentiality, in line with this duty the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Rimegepant (Vydura) – any disease

Response:

Information not held

Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY

Response:

98 patients attended a Botox clinics in 4 months (June-Sept) but without a manual review of these records we are unable to provide the level of information requested.

As such we cannot provide this information as the cost of locating and retrieving this exceeds the "appropriate limit" as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

B. How many patients have you treated in the last 4 months for acute migraine with:

Rimegepant (Vydura)

Response:

Information not held

C. Are you required to complete Blueteq for the following product classes:

Botulinum Toxin (Botox, Dysport, Xeomin)

Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab)

Gepants (e.g. rimegepant, atogepant)

Response:

No, we do not use the Blueteq in Northern Ireland

Email: Foi.Team@Southerntrust.hscni.net